Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...

Septerna is seeking a valuation of $743.1 million in its upsized U.S. initial public offering, the Goldman Sachs-backed drug ...

Septerna upped the size of its offering twice before pricing a stock sale that raised funds for its lead candidate, a ...

Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor ...

Septerna, a nearly three year-old drug developer backed by Goldman Sachs, is aiming for a valuation of up to $628 million as ...

(Reuters) -Goldman Sachs-backed drug developer Septerna said on Thursday it was seeking a valuation of $743.1 million in its ...

Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of ...

Septerna Inc. shares soared as much as 42% in their trading debut after the biotechnology company raised $288 million in an ...

Three sizable IPOs priced this past week, joined by a flurry of small issuers and blank check companies - Ingram Micro, ...

Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on ...

Recent developments in healthcare cover a broad spectrum of issues: an analysis reveals that weight-loss drugs like Wegovy do ...

Septerna is seeking a valuation of $743.1 million in its upsized U.S. initial public offering, the Goldman Sachs-backed drug ...